FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de peptides

Lipo-C

Lipotropic Complex / MIC Injection

Beauty & Skincare

Lipo-C (Lipotropic Compound) is an injectable formulation combining methionine, inositol, and choline (MIC) with B-complex vitamins (typically B1, B2, B5, B6, and B12), designed to support fat metabolism, liver function, and energy production. It is commonly prescribed by weight loss clinics and functional medicine practitioners as an adjunct to diet and exercise programs. While not a peptide in the strict biochemical sense, Lipo-C is frequently categorized alongside peptide therapies in clinical weight management protocols.

Mécanisme d'action

Lipotropic injection containing methionine, inositol, choline, and commonly supplemented with L-carnitine, B12, and B-complex vitamins. Enhances hepatic fat metabolism, supports methylation pathways, and promotes bile flow for improved lipid processing.

Protocoles de recherche

Pour des fins de recherche uniquement. Pas de conseil médical.

Protocols typically use 1ml intramuscular injection weekly. Some protocols use twice weekly during active weight management. Often combined with dietary and exercise programs.

Notes de recherche

Clinical Research Status

Lipotropic injections have been used in clinical practice for decades, though high-quality randomized controlled trials specifically evaluating the MIC + B-vitamin combination for fat loss are limited. Individual components have established biochemical roles in fat metabolism: methionine as a lipotropic amino acid, inositol as a secondary messenger in insulin signaling, and choline as essential for VLDL assembly and hepatic fat export. The combination is prescribed under physician supervision at compounding pharmacies but is not FDA-approved as a specific weight loss drug.

Key Published Findings

Methionine serves as a methyl donor essential for phosphatidylcholine synthesis and fat mobilization from hepatocytes, with deficiency directly linked to hepatic steatosis in animal models. Inositol research demonstrates improved insulin sensitivity and reduced body weight in polycystic ovary syndrome (PCOS) patients at doses of 2-4g daily in multiple randomized trials. Choline deficiency is associated with fatty liver disease, and adequate choline status supports VLDL secretion necessary for hepatic fat clearance.

Safety Profile

MIC injections are generally well-tolerated, with the most common side effects being injection site soreness, mild gastrointestinal discomfort, and occasional headache. B-vitamin components are water-soluble with wide therapeutic margins, though B6 neurotoxicity is possible at very high chronic doses. Methionine supplementation should be used cautiously in individuals with elevated homocysteine levels unless adequate B6, B12, and folate are co-administered to support the methylation cycle.

Comparison to Related Compounds

Lipo-C differs from single-agent weight loss peptides like semaglutide or tirzepatide by targeting hepatic fat metabolism rather than appetite suppression or incretin signaling. Compared to L-carnitine injections which facilitate mitochondrial fatty acid transport, MIC components address earlier steps in fat mobilization and export from the liver. Injectable administration provides higher bioavailability than oral supplements, particularly for B12 in patients with absorption issues, though the clinical significance of this advantage for the other components is debated.

Community Observations

Users at weight loss clinics typically receive weekly or twice-weekly injections as part of comprehensive programs including caloric restriction and exercise. Many report increased energy levels within hours of injection, likely attributable to B-vitamin components rather than fat metabolism effects which would be more gradual. Results are generally described as supportive rather than dramatic, with most practitioners positioning Lipo-C as a metabolic optimization tool rather than a primary weight loss intervention.

Moitié de vie

N/A (vitamin complex)

Réconstitution

Pre-mixed solution (no reconstitution required)

Conservation

Lyophilisé

Refrigerate 2-8C. Protect from light.

Réconstitué

Refrigerate 2-8C. Stable for 90 days.

Statut légal aux États-Unis

Supplement/compounded medication

Autres noms connus

Lipotropic ComplexMIC Injection

Questions fréquentes

Qu'est-ce que Lipo-C ?

Lipo-C (Lipotropic Compound) is an injectable formulation combining methionine, inositol, and choline (MIC) with B-complex vitamins (typically B1, B2, B5, B6, and B12), designed to support fat metabolism, liver function, and energy production. It is commonly prescribed by weight loss clinics and functional medicine practitioners as an adjunct to diet and exercise programs. While not a peptide in the strict biochemical sense, Lipo-C is frequently categorized alongside peptide therapies in clinical weight management protocols.

Comment agit Lipo-C ?

Lipotropic injection containing methionine, inositol, choline, and commonly supplemented with L-carnitine, B12, and B-complex vitamins. Enhances hepatic fat metabolism, supports methylation pathways, and promotes bile flow for improved lipid processing.

Quel est le statut réglementaire de Lipo-C aux États-Unis ?

Supplement/compounded medication

Quelle est la demi-vie de Lipo-C ?

N/A (vitamin complex)

Sous quels autres noms Lipo-C est-il connu ?

Lipotropic Complex, MIC Injection

Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.

Lire la déclaration complète